Estrogen Receptor-positive Breast Cancer
📧 Sign up to get email alerts when something new happens for Estrogen Receptor-positive Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-05-16Clinical Trial Update: Evaluation of Endocrine Therapy Effects of Host Immunity in Early Stage Breast Cancer
This update reports on a completed clinical trial evaluating how endocrine therapy influences host immune responses in early-stage breast ca…
-
CLINICAL_TRIALS research · 2024-05-08Clinical Trial Update: QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast Cancer [Phase 2]
A Phase 2 study evaluating QL1706 in combination with chemotherapy as neoadjuvant therapy for early high-risk estrogen receptor-positive, HE…
-
CLINICAL_TRIALS trial_result · 2023-12-13Clinical Trial Update: 68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating 68-Ga-RM2 PET/MRI for imaging estrogen receptor-positive breast cancer has completed with results post…
-
FDA approval · 2023-11-09FDA Approved: ORSERDU — Supplemental Application (Stemline Therapeutics, Inc.)
The FDA approves a supplemental application for ORSERDU (elacestrant) submitted by Stemline Therapeutics, Inc.
-
CLINICAL_TRIALS trial_result · 2023-11-09Clinical Trial Update: Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca [Phase 2]
Phase 2 trial evaluating neoadjuvant pembrolizumab plus decitabine followed by standard neoadjuvant chemotherapy for locally advanced HER2-n…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-08-31Clinical Trial Update: Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer [Phase 2]
Phase 2 trial investigating pembrolizumab with or without vorinostat and tamoxifen for estrogen receptor-positive breast cancer; trial termi…
-
CLINICAL_TRIALS trial_result · 2023-03-30Clinical Trial Update: Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer [Phase 2]
Phase 2 study comparing amcenestrant to physician's choice in locally advanced or metastatic estrogen receptor-positive breast cancer. The t…
-
CLINICAL_TRIALS trial_result · 2023-03-10Clinical Trial Update: A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer) [Phase 2]
This clinical trial update reports on a Phase 2 study comparing giredestrant with physician's choice of endocrine therapy in previously trea…
-
CLINICAL_TRIALS trial_result · 2023-02-21Clinical Trial Update: Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy [Phase 2]
Phase 2 clinical trial update describing the use of serial FES PET/CT imaging to assess estrogen receptor expression in patients with estrog…
-
CLINICAL_TRIALS trial_result · 2023-02-21Clinical Trial Update: Dalpiciclib in Combination With Exemestane and Trastuzumab Plus Pyrotinib in Early Triple Positive Breast Cancer [Phase 2]
Phase 2 trial exploring dalpiciclib in combination with exemestane, trastuzumab, and pyrotinib for early triple-positive breast cancer (ER+,…
-
CLINICAL_TRIALS trial_result · 2023-02-02Clinical Trial Update: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer) [Phase 2]
Phase 2 trial comparing giredestrant plus palbociclib to anastrozole plus palbociclib in untreated postmenopausal ER-positive, HER2-negative…
-
FDA approval · 2023-01-27FDA Approved: ORSERDU — Original Application (Stemline Therapeutics, Inc.)
FDA approved ORSERDU (elacestrant) for ER-positive, HER2-negative advanced or metastatic breast cancer following aromatase inhibitor therapy…
-
CLINICAL_TRIALS trial_result · 2022-06-02Clinical Trial Update: PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer [Phase 2]
Phase 2 trial evaluating palbociclib in combination with anastrozole for Stage 2-3 estrogen receptor-positive, HER2-negative breast cancer; …
-
CLINICAL_TRIALS trial_result · 2022-05-18Clinical Trial Update: Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer [Phase 2]
Phase 2 clinical trial evaluating ribociclib in combination with an aromatase inhibitor for older adults with estrogen receptor-positive, HE…
-
CLINICAL_TRIALS trial_result · 2022-04-05Clinical Trial Update: Phase II Study of Everolimus Beyond Progression [Phase 2]
Phase II trial evaluating Everolimus beyond progression in breast cancer was terminated with posted results.
-
CLINICAL_TRIALS trial_result · 2022-03-22Clinical Trial Update: ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study) [Phase 1, Phase 2]
Phase 1/2 trial update for an ER+/HER2- breast cancer candidate (ENZENO) in locally advanced or metastatic disease; current status unknown.
-
CLINICAL_TRIALS trial_result · 2021-10-15Clinical Trial Update: Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer [Phase 2]
Phase 2 trial investigating palbociclib with either letrozole or fulvestrant in estrogen receptor-positive, HER2-negative metastatic breast …
-
CLINICAL_TRIALS trial_result · 2021-10-13Clinical Trial Update: Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast Cancer [Phase 2]
Phase 2 clinical trial evaluating neoadjuvant trastuzumab, pyrotinib plus palbociclib and fulvestrant in HER2-positive, ER-positive breast c…
-
CLINICAL_TRIALS trial_result · 2021-09-28Clinical Trial Update: Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer [Phase 2]
Phase 2 trial evaluating tamoxifen citrate or Z-Endoxifen hydrochloride in locally advanced or metastatic estrogen receptor-positive, HER2-n…
-
CLINICAL_TRIALS trial_result · 2021-09-27Clinical Trial Update: A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy [Phase 2]
Phase II trial comparing venetoclax plus fulvestrant versus fulvestrant alone in ER+/HER2-negative locally advanced or metastatic breast can…
-
CLINICAL_TRIALS trial_result · 2021-08-11Clinical Trial Update: Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer [Phase 1, Phase 2]
Clinical trial evaluating atezolizumab with cobimetinib or idasanutlin in stage IV or unresectable recurrent estrogen receptor-positive brea…
-
CLINICAL_TRIALS trial_result · 2021-08-03Clinical Trial Update: Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases [Phase 2]
Phase 2 clinical trial evaluating neoadjuvant response-guided treatment for luminal B and luminal A tumors with node metastases in early-sta…
-
FDA approval · 2021-07-29FDA Approved: FULVESTRANT — Original Application (Zydus Lifesciences Limited)
The FDA approved a generic fulvestrant product from Zydus Lifesciences Limited under an Original Application for the treatment of estrogen r…
-
CLINICAL_TRIALS trial_result · 2021-07-27Clinical Trial Update: TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer [Phase 2]
Phase 2 trial evaluating TAK-228 in combination with tamoxifen for ER-positive, HER2-negative breast cancer has completed with results poste…
-
CLINICAL_TRIALS trial_result · 2021-06-18Clinical Trial Update: Assessment of Safety and Efficacy of Estetrol in Postmenopausal Women With Advanced Estrogen Receptor Positive (ER+) Breast Cancer [Phase 1, Phase 2]
Clinical trial update evaluating safety and efficacy of estetrol in postmenopausal women with advanced estrogen receptor-positive breast can…